Evidence map›Paper›PMID 30465248›Full record

ArticleJournal of endocrinological investigation2019

Type 2 diabetes treatment and progression of chronic kidney disease in Italian family practice.

G Ermini, C Tosetti, D Zocchi, M Mandreoli, M T Caletti, G Marchesini, Bologna Section of the Italian College of General Practitioners and Primary Care

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

G ErminiSection of the Italian College of General Practitioners and Primary Care, S.Orsola-Malpighi Hospital, "Alma Mater" University, 9, Via Massarenti, 40138, Bologna, Italy. giulio.marchesini@unibo.it.ORCID http://orcid.org/0000-0003-2407-9860
C TosettiSection of the Italian College of General Practitioners and Primary Care, S.Orsola-Malpighi Hospital, "Alma Mater" University, 9, Via Massarenti, 40138, Bologna, Italy.
D ZocchiSection of the Italian College of General Practitioners and Primary Care, S.Orsola-Malpighi Hospital, "Alma Mater" University, 9, Via Massarenti, 40138, Bologna, Italy.
M MandreoliNephrology and Dialysis Unit, S. Maria della Scaletta Hospital, Imola, Bologna, Italy.
M T CalettiUnit of Metabolic Diseases and Clinical Dietetics, "Alma Mater" University, Bologna, Italy.
G MarchesiniUnit of Metabolic Diseases and Clinical Dietetics, "Alma Mater" University, Bologna, Italy.
Bologna Section of the Italian College of General Practitioners and Primary Care

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsProgressive chronic kidney disease represents a dreadful complication of type 2 diabetes mellitus (T2DM). We tested the pattern of use and the renal effects of old glucose-lowering drugs in T2DM patients cared for by Italian general practitioners (GPs).

methodsData of 2606 T2DM patients were extracted from the databases of GPs, who do not have access to the most recent glucose-lowering drugs in Italy. The rate of kidney function decline was calculated by CKD-EPI

resultsMetformin was used in 55% of cases, either alone or with sulfonylureas/repaglinide, across the whole spectrum of CKD (from 66% in stage G1 to only 8% in G4). Sulfonylurea use peaked at 21-22% in stage G2-G3a, whereas repaglinide use significantly increased from 8% in G1 to 22% in G4. The median rate of CKD decline was - 1.64 mL/min/1.73 m

conclusionIn the setting of Italian family practice, sulfonylurea use is associated with progressive CKD in patients with T2DM. Metformin, at doses progressively reduced according to CKD stages, as recommended by guidelines, is not associated with fast progression.

Indexed as

AgedBiomarkersDiabetes Mellitus, Type 2Disease ProgressionFamily PracticeFemaleFollow-Up StudiesGlomerular Filtration RateHumansHypoglycemic AgentsIncidenceItalyMalePrognosisRenal Insufficiency, ChronicBiomarkersHypoglycemic AgentsAlbumin excretionBody mass indexCardiovascular preventionGlomerular filtration rateGlucose-lowering drugsMetformin

Identifiers

PMID30465248

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.